Literature DB >> 11051237

P73 gene expression in ovarian cancer tissues and cell lines.

C L Chen1, S M Ip, D Cheng, L C Wong, H Y Ngan.   

Abstract

Thep73 gene, a homology of p53, is a new candidate of imprinting and tumor suppressor gene. To investigate the role of p73 in ovarian cancer, we studied the allelic expression in 56 cases of ovarian cancer using StyI polymorphism analysis. We also examined p73 expression by semi-quantitative reverse transcription-PCR as well as by Western blot analysis and DNA methylation study of the CpG island in exon 1 in ovarian cancer tissues and cell lines. Loss of heterozygosity was found in 8.3% (2 of 24) of the cases. Biallelic expression was demonstrated in 91.7% (22 of 24) of the tumor samples, in 70.8% (17 of 24) of the normal samples, and in 1 ovarian cancer cell line. Imbalanced expression and monoallelic expression were found in three and two pairs of matched samples, respectively. Overexpression of p73 was found in advanced ovarian cancer rather than in early-stage disease or in borderline ovarian tumor. No significant difference was found in the p53 expression. Three cell lines with absent p73 protein expression and one tumor sample with monoallelic expression were methylated in the CpG island. Demethylation in SKOV3 cell line using 5-azacytidine can reactivate the expression of this gene in both the mRNA and the protein level. Our results indicated that p73 was not imprinted in most of the ovarian cancer and normal tissues, but it could be involved in the advanced ovarian cancer through overexpression. DNA methylation may contribute to the lack of p73 expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11051237

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

1.  The human p73 promoter: characterization and identification of functional E2F binding sites.

Authors:  Ratnam S Seelan; Meredith Irwin; Petra van der Stoop; Chiping Qian; William G Kaelin; Wanguo Liu
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

2.  Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter.

Authors:  Takahito Nakagawa; Masato Takahashi; Toshinori Ozaki; Ken-ichi Watanabe Ki; Satoru Todo; Hiroyuki Mizuguchi; Takao Hayakawa; Akira Nakagawara
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  p73α1, a p73 C-terminal isoform, regulates tumor suppression and the inflammatory response via Notch1.

Authors:  Kyra Nicole Laubach; Wensheng Yan; Xiangmudong Kong; Wenqiang Sun; Mingyi Chen; Jin Zhang; Xinbin Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-26       Impact factor: 12.779

4.  The expression of p73, p21 and MDM2 proteins in gliomas.

Authors:  Makoto Kamiya; Yoichi Nakazato
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

5.  c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation.

Authors:  Tamara Lotan; Jonathan Hickson; Jeffrey Souris; Dezheng Huo; Jennifer Taylor; Terry Li; Kristen Otto; Seiko Diane Yamada; Kay Macleod; Carrie W Rinker-Schaeffer
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

6.  p73alpha is a candidate effector in the p53 independent apoptosis pathway of cisplatin damaged primary murine colonocytes.

Authors:  A Oniscu; N Sphyris; R G Morris; S Bader; D J Harrison
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

7.  A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.

Authors:  Alice Soragni; Deanna M Janzen; Lisa M Johnson; Anne G Lindgren; Anh Thai-Quynh Nguyen; Ekaterina Tiourin; Angela B Soriaga; Jing Lu; Lin Jiang; Kym F Faull; Matteo Pellegrini; Sanaz Memarzadeh; David S Eisenberg
Journal:  Cancer Cell       Date:  2015-12-31       Impact factor: 31.743

8.  P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.

Authors:  S Al-Bahlani; M Fraser; A Y C Wong; B S Sayan; R Bergeron; G Melino; B K Tsang
Journal:  Oncogene       Date:  2011-04-25       Impact factor: 9.867

9.  PROM1, CXCL8, RUNX1, NAV1 and TP73 genes as independent markers predictive of prognosis or response to treatment in two cohorts of high-grade serous ovarian cancer patients.

Authors:  Agnieszka Dansonka-Mieszkowska; Laura Aleksandra Szafron; Magdalena Kulesza; Anna Stachurska; Pawel Leszczynski; Agnieszka Tomczyk-Szatkowska; Piotr Sobiczewski; Joanna Parada; Mariusz Kulinczak; Joanna Moes-Sosnowska; Barbara Pienkowska-Grela; Jolanta Kupryjanczyk; Magdalena Chechlinska; Lukasz Michal Szafron
Journal:  PLoS One       Date:  2022-07-22       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.